Tirzepatide

Tirzepatide

Drug monograph · NCLEX study reference
Trade names	Mounjaro, Zepbound
Therapeutic class	Antidiabetic, weight management
Pharmacologic class	Dual GIP and GLP-1 receptor agonist
Onset / peak / duration	Weekly SubQ; effect builds over titration.
Half-life / level	Half-life about 5 days; no routine level.
Routes	SubQ
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	None.
Pregnancy / lactation	Discontinue.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Tirzepatide (brand names Mounjaro, Zepbound) — Antidiabetic, weight management; Dual GIP and GLP-1 receptor agonist.

Identification

• Therapeutic class: Antidiabetic, weight management.
• Pharmacologic class: Dual GIP and GLP-1 receptor agonist.

Pharmacology

• Mechanism of action: Activates both GIP and GLP-1 receptors for strong glucose-lowering and appetite-reducing effects.
• Onset / peak / duration: Weekly SubQ; effect builds over titration.
• Half-life / therapeutic level: Half-life about 5 days; no routine level.

Clinical use

• Indications: Type 2 diabetes (Mounjaro), chronic weight management (Zepbound).
• Usual dose, route, frequency: SubQ 2.5 mg weekly, titrated up to 15 mg weekly.
• Maximum dose / adjustments: Titrate every 4 weeks for tolerance.

Safety

• Contraindications: Medullary thyroid carcinoma history, MEN 2.
• Black box warning: Thyroid C-cell tumor risk (rodents).
• Interactions: Delayed gastric emptying, insulin and secretagogues; may reduce oral contraceptive effectiveness (counsel on backup method).
• Pregnancy / lactation: Discontinue.
• High-alert: No.

Adverse effects

• Common side effects: Nausea, diarrhea, decreased appetite, constipation.
• Serious effects to report: Pancreatitis, gallbladder disease, severe GI symptoms.
• Antidote / reversal: None.

Nursing process

• Assessment before administration: Thyroid and pancreatitis history, contraception in those who can become pregnant.
• Interventions during therapy: Titrate slowly; rotate sites.
• Monitor: A1c, weight, GI tolerance.
• Evaluation / expected outcome: Glycemic control and significant weight loss.

Patient teaching

• Patient teaching: Weekly same-day injection; use backup contraception during titration.
• Notify provider if: Severe abdominal pain, neck lump.
• Administration tips: SubQ; rotate sites.